Industry · July 23, 2026

Filler Migration: Where the Product Actually Goes, and Why It Outlasts the Brochure

Filler migration is the reason a lip looks wider every year without anyone adding volume to the border, and the reason an under-eye stays puffy long after the syringe was supposed to have disappeared. Imaging studies keep finding hyaluronic acid in faces years after the quoted duration expired. Here is what moves, what stays, why the marketed longevity and the biological longevity are different numbers, and what dissolving can and cannot undo.

By The Editorial Desk

8 min read

Filler migration is one of the few aesthetic complications a patient can usually see before an injector will name it. The upper lip that has developed a soft shelf above the vermilion border. The philtrum that has lost its columns. The under-eye that reads swollen in morning light years after the last appointment. Patients describe these as aging, or as puffiness, or as something being wrong with their skin. In a meaningful share of cases the correct description is simpler: the product is still there, and it is not where it was put. That claim used to be contested. Imaging has largely settled it.

The marketed duration and the biological duration are not the same number

The short answer: the six to eighteen month figure on a product label describes when the visible correction fades, not when the material leaves the tissue.

Those two things were assumed to be the same for most of the last two decades, largely because nobody was routinely imaging treated faces. That changed as magnetic resonance imaging and high frequency ultrasound entered the aesthetic literature. MRI based studies published in the aesthetic and dermatologic journals have repeatedly identified hyaluronic acid deposits in the midface and periorbital region years after injection, with individual cases documented well beyond a decade. Ultrasound has since become common enough in specialist practices that mapping old product before treating a new patient is a defensible standard rather than an eccentricity.

The mechanism is not mysterious. Hyaluronic acid in the body has a tissue half life measured in days. Injectable filler is not that molecule in its native state. It is cross linked, usually with butanediol diglycidyl ether, specifically so that it resists the enzymes that would otherwise clear it in under a week. Cross linking density, particle size, and concentration are the levers manufacturers pull to set firmness and longevity, and they are also the levers that determine how slowly the material yields to hyaluronidase and oxidative degradation. A product engineered to survive a year in a mobile lip will survive considerably longer in a static, poorly vascularized plane over bone.

There is a second layer to this. Even where product has genuinely resorbed, the tissue does not always return to baseline. Filler placement produces a foreign body response and a degree of fibrosis and neocollagenesis around the deposit. Some of the volume a long term patient carries is scar and collagen rather than gel, which is why a face that is fully dissolved sometimes still does not look like the face in the pre treatment photographs.

"
The label duration describes when a patient stops seeing the correction they paid for. It does not describe when the material stops occupying the face. Those two dates can be a decade apart.
"

Filler migration is a placement problem before it is a product problem

The short answer: filler moves when it is placed in a plane that moves, in a volume the plane cannot hold, with a rheology that was chosen for the wrong depth.

The lip is the demonstration case because the failure is visible from across a room. Product intended for the body of the lip drifts above the vermilion border when it is deposited too superficially, in boluses that exceed what the compartment can accommodate, into tissue that contracts thousands of times a day with speech and eating. The orbicularis oris is a sphincter. It does not hold a bolus still. Add a soft, low cohesivity gel chosen for smoothness rather than for the ability to stay put, repeat the treatment every nine months for six years on the assumption that the previous rounds are gone, and the result is the elongated, shelf like upper lip that has become recognizable enough to have its own internet vocabulary.

Three variables account for most of it. Depth, because product on periosteum behaves differently than product in the subcutaneous plane under an active muscle. Volume per site, because large boluses displace along tissue planes and along lymphatic channels while small aliquots integrate. And rheology, because cohesive, higher G prime products resist deformation and are built for structural placement on bone, while softer products are built for fine lines and will not stay stacked. An injector who uses one product for the entire face is making a purchasing decision, not a clinical one.

Gravity gets more credit than it deserves in patient explanations and less than it deserves in one specific setting: heavy structural volume placed in the mobile lower midface of a patient whose skin has already lost support. That combination does descend, and it descends faster than the same volume placed deep on the maxilla.

The patient-framing test: Before you book another syringe, put three questions to the injector and listen to how specific the answers get. First: "What plane are you injecting, and why that plane for this product?" A clinician who is planning will answer with anatomy (supraperiosteal, deep medial cheek, submuscular) and will explain why this particular gel suits that depth. A clinician who answers with a brand name and a volume is treating a menu, not a face. Second: "What is already in my face, and how do you know?" If you have been injected for more than three or four years across more than one practice, nobody can answer that from memory or from your recollection. Ask whether they can image it, or whether they have colleagues who can. A practice that treats "it has all dissolved by now" as a fact rather than an assumption is going to keep adding to a total it cannot see. Third: "If I do not like this in six months, what is the exit?" For hyaluronic acid there is a real answer involving hyaluronidase, staged sessions, and a period of looking worse before better. For calcium hydroxylapatite, poly-L-lactic acid, and anything described as permanent or semi permanent, the honest answer is that there is no reliable exit, which is information you want before the appointment rather than after it.

The under-eye is where this goes wrong most often

The short answer: the infraorbital region has thin skin, weak lymphatic drainage, and constant muscle motion, which is the exact combination that turns retained product into chronic swelling.

Tear trough correction is the most technically demanding injectable in routine practice, and it is offered by the widest range of practitioners of any injectable in routine practice. That mismatch produces predictable outcomes. Hyaluronic acid is hydrophilic, meaning it binds water. Placed superficially under eyelid skin that is a fraction of a millimeter thick, the same property that gives the product its volume creates persistent edema, particularly in patients who already have compromised lymphatic drainage in the midface. The result presents as puffiness that varies with salt intake, sleep, and time of day, which is exactly how patients describe ordinary aging, which is why it goes unrecognized for years.

Two other signatures point to product rather than anatomy. The Tyndall effect, a bluish or grayish cast where gel sits too close to the surface and scatters short wavelength light, is essentially pathognomonic for superficial placement. And malar edema, a shelf of swelling sitting over the cheekbone at the boundary of the tear trough, is a well documented consequence of product overwhelming a lymphatic watershed. The American Academy of Dermatology and the periorbital injectable literature have both been consistent that this region rewards conservative volumes, deep placement, and firmer products, and punishes everything else. It is also a region where the vascular anatomy makes the far more serious complication, arterial occlusion with visual compromise, a documented risk rather than a theoretical one. Migration and occlusion are different problems, but they share a root cause: injectors treating a high risk anatomic zone as a routine one.

Dissolving is a real tool with real limits

The short answer: hyaluronidase reverses hyaluronic acid and nothing else, it often takes more than one session, and the face after dissolving is not automatically the face before treatment.

Hyaluronidase is a genuine advantage of the hyaluronic acid class and the main reason experienced injectors prefer it to alternatives for most facial work. It is also less precise than patients assume. Older, densely cross linked deposits resist it and frequently require repeat treatment at intervals. The enzyme does not distinguish perfectly between injected product and the patient's native hyaluronic acid, which is why a face immediately after aggressive dissolving can look deflated and drawn for several weeks before it settles. Allergic reactions are uncommon but real, and the drug is prescription territory that belongs in trained hands with anaphylaxis management on site.

What hyaluronidase cannot touch is the rest of the market. Calcium hydroxylapatite, poly-L-lactic acid, polymethylmethacrylate, and silicone have no antidote. Where those products migrate or nodulate, the options narrow to steroid injection, dilution, watchful waiting, or surgical excision, and excision in a mobile facial plane trades one problem for a scar. This asymmetry is the single strongest argument for restricting non reversible products to practitioners with specific experience in them and to patients who have understood the tradeoff in plain language.

The regulatory backdrop deserves a mention because it is where the worst outcomes cluster. The FDA has issued repeated safety communications on dermal fillers, including explicit warnings against products purchased online for self injection and against pen style devices that force material through the skin without a needle. Those devices offer no control of depth, which in a category where depth is the primary determinant of whether product stays put is the whole problem in one sentence.

The honest summary

Filler migration is not a rare complication of an otherwise predictable treatment. It is the expected consequence of a specific set of decisions: superficial placement, boluses too large for the compartment, soft product used where firm product belongs, and a treatment cadence built on the assumption that last year's syringes are gone. Imaging has made the last assumption difficult to defend. Hyaluronic acid persists in tissue well past the interval on the label, often for years, occasionally for more than a decade, and the visible fading of a correction is not evidence that the material has left.

The practical conclusions are unglamorous. Treat cumulative volume as a running total rather than as a series of independent transactions, and keep a written record of product and volume by year, because no injector will reconstruct it for you later. Insist that the person holding the syringe can name the plane and justify the product for that plane. Be conservative in the under-eye or find someone who is, since it is the region where retained product masquerades as aging for the longest. Understand that reversibility is a property of one product class only, and that choosing anything outside that class is choosing to live with the result. And if a face has been injected continuously for a decade and now looks heavier, wider, or older than it should, the most useful next appointment is frequently not the one that adds anything. It is the one that starts by finding out what is already in there.

All dispatches